Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease-Reference-Cited by-同舟云学术

Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease

Published:2020-11-10 Issue: Volume: Page:70-78
ISSN:2054-6181
Container-title:EMJ Diabetes
language:
Short-container-title:EMJ Diabet

Author:

Derosa Giuseppe¹,Rivera Rodolfo²,D'Angelo Angela¹,Maffioli Pamela³

Affiliation:

1. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy

2. Division of Nephrology and Dialysis San Gerardo Hospital, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, Italy

3. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Abstract

Type 2 diabetes mellitus is currently the main cause of chronic kidney disease, leading to end-stage renal disease in most countries around the world. Metformin is the most commonly prescribed oral antihyperglycaemic in the world and after approval by the U.S. Food and Drug Administration (FDA) in 1994, it is currently recommended as the first-line pharmacological agent for newly diagnosed Type 2 diabetes mellitus by many professional diabetes associations. In this review, the authors analysed efficacy and safety of metformin in patients with chronic kidney disease.

Publisher

European Medical Group

Reference61 articles.

1. Collins AJ et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1):e1-420.

2. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney. 2012;60(5):850-86.

3. American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care. 2020;43(Suppl 1):S1-2.

4. Cosentino F et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255-323.

5. Eisenreich A, Leppert U. Update on the protective renal effects of metformin in diabetic nephropathy. Curr Med Chem. 2017;24(31):3397-412.